Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957331 · ClinicalTrials.gov registry record · Phase 4
Beta Blockade in in Traumatic Brain Injury
A Phase 4 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT02957331: Completed Phase 4 study, sponsored by University of Tennessee.
NCT02957331 is a Phase 4 study that has completed, run by University of Tennessee. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02957331, a Phase 4 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is test the effect of beta-adrenergic blockade on mortality in patients with traumatic brain injury with the hypothesis being that the addition of beta blockade to the treatment regime of this patient population will lower mortality and supress the catecholamine surge that accompanies traumatic brain injury as compared to those who do not receive beta blockade. Half the patients will be randomized to receive propranolol and half will be randomized to receive no beta blocker.
Primary Outcome
Mortality will be assessed at day 30 or at hospital discharge
Interventions
- DRUG Propranolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-05 |
| Phase | Phase 4 |
What the finished NCT02957331 record still lists
NCT02957331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Propranolol is the first listed.
NCT02957331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02957331 about?
NCT02957331 is a clinical study titled "Beta Blockade in in Traumatic Brain Injury". The purpose of this study is test the effect of beta-adrenergic blockade on mortality in patients with traumatic brain injury with the hypothesis being that the addition of beta blockade to the treatment regime of this patient population will lower mortality and supress the catecholamine surge that ...
What is the current status of trial NCT02957331?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2016-01. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02957331?
The interventions under investigation include: Propranolol (DRUG).
Who is sponsoring clinical trial NCT02957331?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02957331's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia